Baptiste Leurent

University College London

Papers

1

Total Citations

39

H-Index

1

About

Baptiste Leurent is a leading clinical researcher in urological oncology, with a primary focus on improving functional outcomes following robot-assisted radical prostatectomy (RARP) for localised prostate cancer. His most significant contribution is the landmark NeuroSAFE PROOF trial, a multicentre, patient-blinded, randomised controlled phase 3 study published in 2025. This work rigorously evaluated the NeuroSAFE technique—a standardised intraoperative frozen section analysis designed to guide nerve-sparing during surgery. Leurent’s research demonstrated that NeuroSAFE-guided RARP significantly improves postoperative erectile function and early urinary continence recovery compared to standard RARP, offering a crucial evidence-based advancement in surgical precision. With 39 citations for this seminal paper, his work is already shaping clinical guidelines and surgical practice. By addressing the delicate balance between oncological control and quality of life, Leurent has provided surgeons with a validated tool to preserve neurovascular bundles without compromising cancer clearance. His research stands at the forefront of functional urology, directly impacting the long-term wellbeing of thousands of men undergoing prostate cancer surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
39
Total Citations
39
Avg Citations/Paper
🏆 Most Cited Paper
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial
39 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 24
🏛 Institutions: University College London

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago